アステラス製薬さんの投稿

Astellas sponsored and actively participated in Tokyo Rainbow Pride 2024 (TRP2024) from April 19-21. Under the inspiring theme of "Don't give up, change Japan," TRP2024 spoke to our unwavering commitment to a society where safety and autonomy are afforded to all, regardless of sexual orientation or gender identity. At the center of our presence was an Astellas booth. Approximately 200 Astellas employees and their families joined the parade, standing shoulder to shoulder to celebrate diversity and unity. At Astellas, Engagement and Diversity, Equity & Inclusion are the cornerstones of our Corporate Strategic Plan 2021. We are proud of initiatives such as our participation in Tokyo Rainbow Pride and other awareness events, and the implementation of a same-sex partnership system. We strive to cultivate an environment where authenticity is celebrated, potential is maximized, and innovation flourishes. We remain steadfast in our commitment to celebrate and leverage diversity, foster innovation, and deliver VALUE to patients and society. #pride2024 #DEI #InnovationThroughDiversity

#News for #investors: Astellas has announced the FY2023 consolidated financial results, ended March 31, 2024. Click on the link below or on the image to learn more:  https://lnkd.in/e_37iWaY

We are excited to announce that Takeda, Astellas, and Sumitomo Mitsui Banking Corporation – SMBC Group have signed a master agreement to establish a joint venture company for incubation of early drug discovery programs in Japan. This collaboration aims to unleash the full potential of innovative technologies and seed assets originating in Japan, advancing them into the global pharmaceutical market and creating high-caliber start-up companies. Takeda and Astellas will provide support leveraging their global expertise to accelerate open innovation in early-stage drug discovery. Read more:  https://lnkd.in/gdMHJSjD #DrugDiscovery #Innovation #Collaboration

Looking beyond short-term wins to long-term opportunity is key in delivering innovation that offers positive, sustainable and meaningful value to patients. Bradley Hardiman, Senior Director, Ventures, Astellas Pharma, shared insights from ambitious innovators, industry leaders, entrepreneurs, and investment experts at premier partnering event #BioEuropeSpring with pharmaphorum. Read on to hear how the deal-making landscape is fairing:   https://bit.ly/3JiJ7wu #ScienceFirstForPatients #ChangingTomorrow

Global Changing Tomorrow Day is Astellas’ signature volunteer event where employees around the world come together to create impact through a variety of service-based activities. In 2023, over 2,800 Astellas employees provided 7,000 hours of volunteering in their communities.  A recurring theme emerged in feedback from our employees on volunteering: the desire for greater interaction with patients. In 2023 we started a partnership with World Patients Alliance through a matching gift as part of the Global Changing Tomorrow Day campaign. In 2024, we plan to continue working with World Patients Alliance and Astellas’ Patient Centricity team for Global Changing Tomorrow Day. We are excited to bring more volunteer opportunities with patients to our employees and help shape the healthcare landscape of tomorrow.  URL Link to corporate website: https://lnkd.in/gNzavC_Y URL Link to World Patients Alliance:   https://lnkd.in/e_JgkryB #ChangingTomorrowDay #EmployeeVolunteering #PatientCentricity #GlobalCTDCampaign #WorldPatientsAlliance

Acute myeloid leukemia (#AML) can be caused by harmful mutations in genes which tell blood cells how to work, affecting more than 20,000 people in the U.S. in 2023. In honor of #AMLWorldAwarenessDay, we encourage you to learn more and help raise awareness about AML. #KnowAML https://lnkd.in/defH4tzy

We are thrilled to announce our strategic research agreement with Invenra, an innovative leader in bispecific antibody technology. This collaboration is a significant step toward advancing our focused research and development initiatives in bispecific therapeutic discovery. Under this agreement, we will have access to Invenra’s B-Body technology, allowing us to drive forward with our commitment to developing innovative and effective treatments for patients in need.  We are excited by the potential of this partnership and look forward to the possibilities it presents for the future of healthcare. Read more:  https://lnkd.in/gaVNUVRv #TherapeuticDiscovery #BispecificAntibody #HealthcareInnovation

We are pleased to introduce Nick Eshkenazi, who has joined our Top Management team as our Chief Digital & Transformation Officer (CDTO), effective April 1, 2024. The CDTO is a new Top Management position designed to better integrate and align our digital and transformation capabilities required to effectively and efficiently transform our business. Nick, who joined Astellas on November 1, 2023, brings over 25 years of experience and expertise in driving complex business transformation, digital and technology initiatives. With a successful track record at respected global organizations such as Woolworths, Costco, Fanatics, PACCAR, and USAA, he has already made a significant impact in enhancing our digital capabilities and reshaping our approach to digital and transformation. Under his leadership, we will continue to evolve our digital and transformation capabilities and drive collaboration across the organization to achieve our business goals. #ChiefDigitalAndTransformationOfficer #management #leadership

Join Dr. Anthony Yanni, Head of Patient Centricity, and Sara Magazin, a recent PharmD graduate and Patient Insights and Solutions (PInS) Fellow, as they share their insights on the evolving landscape of #AI in #healthcare.  The rapid advancement of AI is challenging traditional practices and has the potential to impact patient-centric healthcare. How can professionals navigate this landscape while maintaining patient trust and openly discussing the benefits and limitations of AI in healthcare?  Explore the full discussion on improving patient-centric healthcare through AI:   https://lnkd.in/gnjeutmN #PatientCentricity #HealthcareInnovation